Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jade Laguer"'
Autor:
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, James Medwid, Darin Vanderpool, Ella Lifset, David Trinh, Natalie Hoffman, Xiaolun Wang, J. David Lawson, Robin J. Gunn, Christopher R. Smith, Nicole C. Thomas, Matthew Martinson, Alex Bergstrom, Francis Sullivan, Karyn Bouhana, Shannon Winski, Leo He, Julio Fernandez-Banet, Adam Pavlicek, Jacob R. Haling, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen
Publikováno v:
Nature Medicine. 28:2171-2182
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d677a7e099fb8459d3aaad7bbf29b468
https://doi.org/10.1038/s41591-022-02007-7
https://doi.org/10.1038/s41591-022-02007-7
Autor:
John M. Ketcham, Jacob Haling, Shilpi Khare, Vickie Bowcut, David M. Briere, Aaron C. Burns, Robin J. Gunn, Anthony Ivetac, Jon Kuehler, Svitlana Kulyk, Jade Laguer, J. David Lawson, Krystal Moya, Natalie Nguyen, Lisa Rahbaek, Barbara Saechao, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Laura Vegar, Darin Vanderpool, Xiaolun Wang, Larry Yan, Peter Olson, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:9678-9690
SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe52dccfc91d77da8d18ff2be215969
https://doi.org/10.1021/acs.jmedchem.2c00741
https://doi.org/10.1021/acs.jmedchem.2c00741
Autor:
Xiaolun Wang, Shelley Allen, James F. Blake, Vickie Bowcut, David M. Briere, Andrew Calinisan, Joshua R. Dahlke, Jay B. Fell, John P. Fischer, Robin J. Gunn, Jill Hallin, Jade Laguer, J. David Lawson, James Medwid, Brad Newhouse, Phong Nguyen, Jacob M. O’Leary, Peter Olson, Spencer Pajk, Lisa Rahbaek, Mareli Rodriguez, Christopher R. Smith, Tony P. Tang, Nicole C. Thomas, Darin Vanderpool, Guy P. Vigers, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:3123-3133
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a806650aaec5c7d35ae8ff6555c3535
https://doi.org/10.1021/acs.jmedchem.1c01688
https://doi.org/10.1021/acs.jmedchem.1c01688
Autor:
Shilpi Khare, Niranjan Sudhakar, Jade Laguer, David M. Briere, Larry Yan, Allan Hebbert, Andrew Calinisan, Lars D. Engstrom, Fadia Qiryaqos, Peter Olson, James G. Christensen, Jacob R. Haling
Publikováno v:
Cancer Research. 83:3499-3499
Osimertinib is a third generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor recommended as a first line therapy in patients with advanced non-small lung cancer (NSCLC) characterized by EGFR activating mutations (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ea99e6ddf20a56522bbb06dad376405
https://doi.org/10.1158/1538-7445.am2023-3499
https://doi.org/10.1158/1538-7445.am2023-3499
Autor:
James Christensen, Jill Hallin, Vickie Bowcut, Andrew Calinisan, David Briere, Lauren Hargis, Lars Engstrom, Jade Laguer, James Medwid, Darin Vanderpool, Ella Lifset, David Trinh, Natalie Hoffman, Xiaolun Wang, J. Lawson, Robin Gunn, Christopher Smith, Nicole Thomas, Matthew Martinson, Alex Bergstrom, Francis Sullivan, Karyn Bouhana, Shannon Winski, Leo He, Fernandez-Banet Julio, Adam Pavlicek, Jacob Haling, Lisa Rahbaek, Matthew Marx, Peter Olson
The ability to effectively target mutated KRAS has remained elusive despite decades of research. The recent identification of KRASG12C inhibitors has provided an effective treatment option for patients harboring this particular mutation and has also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10fbcfa8cb41321f46bb73555a3d1e2c
https://doi.org/10.21203/rs.3.rs-1261963/v1
https://doi.org/10.21203/rs.3.rs-1261963/v1
Autor:
Jill, Hallin, Vickie, Bowcut, Andrew, Calinisan, David M, Briere, Lauren, Hargis, Lars D, Engstrom, Jade, Laguer, James, Medwid, Darin, Vanderpool, Ella, Lifset, David, Trinh, Natalie, Hoffman, Xiaolun, Wang, J, David Lawson, Robin J, Gunn, Christopher R, Smith, Nicole C, Thomas, Matthew, Martinson, Alex, Bergstrom, Francis, Sullivan, Karyn, Bouhana, Shannon, Winski, Leo, He, Julio, Fernandez-Banet, Adam, Pavlicek, Jacob R, Haling, Lisa, Rahbaek, Matthew A, Marx, Peter, Olson, James G, Christensen
Publikováno v:
Nature medicine. 28(10)
Recent progress in targeting KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a7ce4f063fa84ad1780e11dbfbdabc8
https://pubmed.ncbi.nlm.nih.gov/36216931
https://pubmed.ncbi.nlm.nih.gov/36216931
Autor:
Xiaolun, Wang, Shelley, Allen, James F, Blake, Vickie, Bowcut, David M, Briere, Andrew, Calinisan, Joshua R, Dahlke, Jay B, Fell, John P, Fischer, Robin J, Gunn, Jill, Hallin, Jade, Laguer, J David, Lawson, James, Medwid, Brad, Newhouse, Phong, Nguyen, Jacob M, O'Leary, Peter, Olson, Spencer, Pajk, Lisa, Rahbaek, Mareli, Rodriguez, Christopher R, Smith, Tony P, Tang, Nicole C, Thomas, Darin, Vanderpool, Guy P, Vigers, James G, Christensen, Matthew A, Marx
Publikováno v:
Journal of medicinal chemistry. 65(4)
KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::28a8a679ffc406047b45ef523fe5e8f2
https://pubmed.ncbi.nlm.nih.gov/36284185
https://pubmed.ncbi.nlm.nih.gov/36284185
Autor:
Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, Darin Vanderpool, Xiaolun Wang, J David Lawson, Nicole Thomas, Robin Gunn, Christopher R. Smith, Julio Fernandez-Banet, Leo He, Adam Pavlicek, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen, Jill Hallin
Publikováno v:
Cancer Research. 82:1131-1131
The ability to effectively target mutated KRAS has remained elusive despite decades of research. Recently, the identification of selective KRASG12C inhibitors has provided an effective treatment option for patients harboring this particular mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b1eca4fb108dd730ff8657fcc5483fc
https://doi.org/10.1158/1538-7445.am2022-1131
https://doi.org/10.1158/1538-7445.am2022-1131
Autor:
Shilpi Khare, Niranjan Sudhakar, David M. Briere, Larry Yan, Lars D. Engstrom, Jade Laguer, James Medwid, Laura Vegar, Darin Vanderpool, Matthew A. Marx, John M. Ketcham, James G. Christensen, Peter Olson, Jacob R. Haling
Publikováno v:
Cancer Research. 82:LB193-LB193
KRAS is the most frequently mutated oncogene in human cancer and facilitates uncontrolled growth through hyperactivation of the MAPK pathway. Recent data has consistently demonstrated co-dependencies of mutant-KRAS with extrinsic proteins that augmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbe107627aea203ba49c9f40899a61e8
https://doi.org/10.1158/1538-7445.am2022-lb193
https://doi.org/10.1158/1538-7445.am2022-lb193
Autor:
John M. Ketcham, David M. Briere, Aaron C. Burns, James G. Christensen, Robin J. Gunn, Jacob Haling, Anthony Ivetac, Shilpi Khare, Jon Kuehler, Svitlana Kulyk, Jade Laguer, John D. Lawson, Krystal Moya, Natalie Nguyen, Peter Olson, Lisa Rahbaek, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Darin Vanderpool, Xiaolun Wang, Matthew A. Marx
Publikováno v:
Cancer Research. 82:LB505-LB505
KRAS mutations are the most common activating mutations in human cancer that ultimately lead to hyperactivation of the MAPK pathway and uncontrolled growth. KRAS functions as a small GTPase that cycles through its GTP-loaded “on” state and its GD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90876ca61e88494e7565b576662f0b19
https://doi.org/10.1158/1538-7445.am2022-lb505
https://doi.org/10.1158/1538-7445.am2022-lb505